YD Bio Limited Ordinary Shares (YDES) 10-Year Financial Performance & Capital Metrics

YDES • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring

AboutBreeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a diseases with unmet medical need. The company is based in Taipei, Taiwan.Show more

Revenue $510K +45.8%
EBITDA -$1M -18252.9%
Net Income -$1M -10509.7%
EPS (Diluted) -0.56 -280100.0%
Gross Margin 30.44% -30.5%
EBITDA Margin -265.93% -12490.7%
Operating Margin -286.45% -10085.3%
Net Margin -276.58% -7241.6%
ROE -42.69% -17761.9%
ROIC -63.31% -47750.1%
Debt/Equity 0.00 -99.8%
Interest Coverage -1893.69 -41131.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Share count reduced 94.1% through buybacks

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-

EPS CAGR

10Y-

5Y-

3Y-

TTM-

ROCE

10Y Avg-9.94%

5Y Avg-9.94%

3Y Avg-15.97%

Latest-44.14%

Peer Comparison

Diagnostics & Immune Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TECHBio-Techne Corporation	10.9B	69.96	152.09	5.23%	6.41%	3.97%	2.35%	0.23
SPRYARS Pharmaceuticals, Inc.	1.1B	11.09	142.00	2970.63%	-56.06%	-54.21%	1.18%	0.00
VCYTVeracyte, Inc.	3.24B	41.00	132.26	23.46%	6.12%	2.41%	1.97%	0.04
CSBRChampions Oncology, Inc.	99.56M	7.17	21.73	13.54%	4.32%	59.65%	7.03%	1.62
MDXGMiMedx Group, Inc.	851.59M	5.75	20.54	8.52%	10.38%	17.09%	7.58%	0.13
LTRNLantern Pharma Inc.	39.26M	3.51	-0.00			-197.36%		0.01
SEERSeer, Inc.	107.44M	1.91	-1.37	-8.13%	-486.02%	-29.19%		0.08
IMDXInsight Molecular Diagnostics Inc.	189.76M	6.62	-1.42	25.15%	-13.81%	-14.81%

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	350.13K	510.36K
Revenue Growth %	-	-	-	-	0.46%
Cost of Goods Sold+	0	0	0	196.69K	355K
COGS % of Revenue	-	-	-	0.56%	0.7%
Gross Profit+	0	0	0	153.44K	155.36K
Gross Margin %	-	-	-	0.44%	0.3%
Gross Profit Growth %	-	-	-	-	0.01%
Operating Expenses+	344.22K	1.72M	2.32M	163.29K	1.62M
OpEx % of Revenue	-	-	-	0.47%	3.17%
Selling, General & Admin	344.22K	1.72M	2.32M	160.56K	1.13M
SG&A % of Revenue	-	-	-	0.46%	2.21%
Research & Development	0	0	0	0	491.35K
R&D % of Revenue	-	-	-	-	0.96%
Other Operating Expenses	0	0	0	2.73K	-493
Operating Income+	-344.22K	-1.72M	-2.32M	-9.85K	-1.46M
Operating Margin %	-	-	-	-0.03%	-2.86%
Operating Income Growth %	-	-4%	-0.35%	1%	-147.46%
EBITDA+	-2.54M	8.7M	3.79M	-7.39K	-1.36M
EBITDA Margin %	-	-	-	-0.02%	-2.66%
EBITDA Growth %	-	4.43%	-0.56%	-1%	-182.53%
D&A (Non-Cash Add-back)	0	0	0	2.45K	104.73K
EBIT	-2.54M	8.7M	3.79M	19.79K	-1.39M
Net Interest Income+	178	764	813	-1.85K	11.04K
Interest Income	178	764	813	290	11.81K
Interest Expense	0	0	0	2.14K	772
Other Income/Expense	-2.19M	10.43M	6.11M	27.5K	75.45K
Pretax Income+	-2.54M	8.7M	3.79M	17.65K	-1.39M
Pretax Margin %	-	-	-	0.05%	-2.72%
Income Tax+	0	0	2.09K	4.09K	25.08K
Effective Tax Rate %	1%	1%	1%	0.77%	1.02%
Net Income+	-2.54M	8.7M	3.79M	13.56K	-1.41M
Net Margin %	-	-	-	0.04%	-2.77%
Net Income Growth %	-	4.43%	-0.56%	-1%	-105.1%
Net Income (Continuing)	-2.54M	8.7M	3.79M	13.56K	-1.41M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.17	0.59	0.41	0.00	-0.56
EPS Growth %	-	4.47%	-0.31%	-1%	-
EPS (Basic)	-0.17	0.59	0.41	0.00	-0.56
Diluted Shares Outstanding	14.63M	14.63M	9.29M	70.1M	4.15M
Basic Shares Outstanding	14.63M	14.63M	9.29M	70.1M	4.15M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	830.77K	129.56K	202.71K	271.72K	3.47M
Cash & Short-Term Investments	693.82K	5.4K	14.13K	87.1K	3.13M
Cash Only	693.82K	5.4K	14.13K	87.1K	3.13M
Short-Term Investments	0	0	0	0	0
Accounts Receivable	0	0	18.07K	98.43K	262.8K
Days Sales Outstanding	-	-	-	102.61	187.95
Inventory	0	0	0	69.4K	37.34K
Days Inventory Outstanding	-	-	-	128.8	38.39
Other Current Assets	0	0	0	0	0
Total Non-Current Assets+	116.76M	117.93M	17.73M	49.49K	3.4M
Property, Plant & Equipment	0	0	0	14.3K	88.08K
Fixed Asset Turnover	-	-	-	24.48x	5.79x
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	2.68M
Long-Term Investments	116.73M	117.93M	17.73M	10.62K	10.53M
Other Non-Current Assets	23.29K	0	0	0	-9.9M
Total Assets+	117.59M	118.06M	17.93M	321.21K	6.86M
Asset Turnover	-	-	-	1.09x	0.07x
Asset Growth %	-	0%	-0.85%	-0.98%	20.37%
Total Current Liabilities+	302.22K	2M	5.55M	298.22K	263.06K
Accounts Payable	0	0	0	17.98K	26.74K
Days Payables Outstanding	-	-	-	33.36	27.5
Short-Term Debt	0	0	0	34.32K	290
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	302.22K	2M	5.55M	344	0
Current Ratio	2.75x	0.06x	0.04x	0.91x	13.18x
Quick Ratio	2.75x	0.06x	0.04x	0.68x	13.04x
Cash Conversion Cycle	-	-	-	198.05	198.84
Total Non-Current Liabilities+	17.51M	7.11M	1.18M	2.2M	10.92K
Long-Term Debt	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	5.68K
Deferred Tax Liabilities	0	0	0	0	1.46K
Other Non-Current Liabilities	17.51M	7.11M	1.18M	2.2M	3.77K
Total Liabilities	17.81M	9.11M	6.74M	298.22K	273.98K
Total Debt+	0	0	0	47.58K	22.55K
Net Debt	-693.82K	-5.4K	-14.13K	-39.52K	-3.11M
Debt / Equity	-	-	-	2.07x	0.00x
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-0.00x	-0.00x	-	-
Interest Coverage	-	-	-	-4.59x	-1893.69x
Total Equity+	99.78M	108.96M	11.2M	22.99K	6.59M
Equity Growth %	-	0.09%	-0.9%	-1%	285.61%
Book Value per Share	6.82	7.45	1.20	0.00	1.59
Total Shareholders' Equity	99.78M	108.96M	11.2M	22.99K	6.59M
Common Stock	115M	115M	17.73M	105.2K	144.18K
Retained Earnings	-15.22M	-6.52M	-6.53M	-515.48K	-1.93M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	0	47.21K	45.07K
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-253.63K	-688.41K	-3.02M	-55.66K	-1.84M
Operating CF Margin %	-	-	-	-0.16%	-3.6%
Operating CF Growth %	-	-1.71%	-3.39%	0.98%	-32%
Net Income	-2.54M	8.7M	3.79M	13.56K	-1.41M
Depreciation & Amortization	0	0	0	2.45K	104.73K
Stock-Based Compensation	0	0	0	0	0
Deferred Taxes	0	0	0	4.09K	26.58K
Other Non-Cash Items	2.19M	-10.02M	-6.11M	50.94K	11.24K
Working Capital Changes	90.42K	632.18K	-697.49K	-126.7K	-567.81K
Change in Receivables	0	0	0	-63.86K	-11.02K
Change in Inventory	0	0	0	-30.57K	28.52K
Change in Payables	67.26K	531.18K	-530.95K	5.39K	10.2K
Cash from Investing+	-116.72M	-1.15M	100.38M	-290	-2.9M
Capital Expenditures	0	0	0	-290	-74.91K
CapEx % of Revenue	-	-	-	0%	0.15%
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	101.78M	528.51K	-2.84M
Cash from Financing+	117.67M	1.15M	-97.34M	113.89K	7.73M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	0	0	0	93.54K	-99.56K
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-253.62K	-688.42K	-3.02M	-55.95K	-4.75M
FCF Margin %	-	-	-	-0.16%	-9.3%
FCF Growth %	-	-1.71%	-3.39%	0.98%	-83.86%
FCF per Share	-0.02	-0.05	-0.33	-0.00	-1.15
FCF Conversion (FCF/Net Income)	0.10x	-0.08x	-0.80x	-4.10x	1.30x
Interest Paid	0	0	0	2.14K	772
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-2.54%	8.34%	6.31%	0.24%	-42.69%
Return on Invested Capital (ROIC)	-	-1.24%	-2.9%	-0.13%	-63.31%
Gross Margin	-	-	-	43.82%	30.44%
Net Margin	-	-	-	3.87%	-276.58%
Debt / Equity	-	-	-	2.07x	0.00x
Interest Coverage	-	-	-	-4.59x	-1893.69x
FCF Conversion	0.10x	-0.08x	-0.80x	-4.10x	1.30x
Revenue Growth	-	-	-	-	45.76%

Frequently Asked Questions

Growth & Financials

YD Bio Limited Ordinary Shares (YDES) reported $0.5M in revenue for fiscal year 2024.

YD Bio Limited Ordinary Shares (YDES) grew revenue by 45.8% over the past year. This is strong growth.

YD Bio Limited Ordinary Shares (YDES) reported a net loss of $3.0M for fiscal year 2024.

Dividend & Returns

YD Bio Limited Ordinary Shares (YDES) has a return on equity (ROE) of -42.7%. Negative ROE indicates the company is unprofitable.

YD Bio Limited Ordinary Shares (YDES) had negative free cash flow of $1.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener